SRRK: Apitegromab nears FDA approval with strong data, global filings, and high launch readiness
Apitegromab is set for FDA review with strong phase III results in SMA, a robust manufacturing transition, and broad anticipated demand across age groups. Regulatory filings are advancing globally, and launch preparations include extensive patient and physician support.Based on Scholar Rock Holding…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.